Online citations, reference lists, and bibliographies.
← Back to Search

Myotax: A Phase II Trial Of Docetaxel Plus Non-pegylated Liposomal Doxorubicin As First-line Therapy Of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines.

E. Curtit, P. Nouyrigat, N. Dohollou, E. Levy, A. Lortholary, J. Gligorov, T. Facchini, D. Jaubert, N. Maille, X. Pivot, V. Grangé, L. Cals
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AIM Non-pegylated liposomal doxorubicin (NPLD) has demonstrated equivalent antitumour activity to conventional doxorubicin and a significantly lower risk of cardiotoxicity when given as a single agent or in combination with cyclophosphamide. This phase II trial was performed to evaluate the efficacy and the safety of NPLD and docetaxel combination in patients with metastatic breast cancer previously exposed to adjuvant anthracyclines. PATIENTS AND METHODS Thirty-four patients received NPLD 60 mg/m(2) and docetaxel 75 mg/m(2) in a 21-day cycle as first-line therapy of metastatic breast cancer. Treatment was planned for six cycles and was continued until progression or toxicity. RESULTS Objective response rate among response-assessable patients was 79% (95% CI (confidence interval), 64-94%) and 27% (95% CI, 11-43%) presented a complete response. Median progression free survival was 11.3 months (95% CI, 6.2-13.3 months) and median overall survival was 28.2 months (95% CI, 16-36.4 months). Symptomatic grade 3 cardiotoxicity occurred in 15% of cases and febrile neutropenia in 47% of the patients. CONCLUSIONS The combination of NPLD and docetaxel demonstrated high antitumour activity in a population of metastatic breast cancer patients exposed to adjuvant anthracyclines and showed an unexpected and unexplained 15% symptomatic left ventricular systolic dysfunction rate.
This paper references
10.1097/00001813-200606000-00014
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1016/S0959-8049(02)00168-5
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
N. Androulakis (2002)
10.1054/bjoc.1999.0958
A unified definition of clinical anthracycline resistance breast cancer
X. Pivot (2000)
10.1200/JCO.2007.11.3787
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
M. De Laurentiis (2008)
10.1200/JCO.2001.19.2.314
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
J. Nabholtz (2001)
10.1200/JCO.2001.19.6.1707
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
J. Jassem (2001)
10.1016/J.BREAST.2004.01.006
First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
D. Vorobiof (2004)
10.1093/annonc/mdp585
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
J. Blohmer (2010)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
10.1016/S0959-8049(97)90007-1
Prospects with docetaxel in the treatment of patients with breast cancer.
M. Marty (1997)
What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及
青儀 健二郎 (2006)
Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
M De Laurentiis (2008)
10.1093/ANNONC/MDJ974
First line chemotherapy of metastatic breast cancer.
P. Pronzato (2006)
10.1007/s00280-008-0887-3
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
P. Schmid (2008)
10.3322/canjclin.55.2.74
Global Cancer Statistics, 2002
D. Parkin (2005)
10.1023/A:1026418831238
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
J. L. Misset (1999)
10.1093/annonc/mdn728
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee (2009)
10.1200/JCO.2002.11.005
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
10.1093/annonc/mdp231
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.
C. de la Fouchardiere (2009)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1038/sj.bjc.6602179
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
J. Bonneterre (2004)
10.1200/JCO.2009.22.7504
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
M. Trudeau (2009)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1200/JCO.2005.06.236
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
M. Bontenbal (2005)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1016/J.EJCA.2005.12.011
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
First line therapy with paclitaxel ( Taxol ) and pegylated liposomal doxorubicin ( Caelyx ) in patients with metastatic
DA Vorobiof
10.2165/00003495-199700544-00003
Anthracyclines in the Treatment of Cancer
G. Hortobagyi (2012)
10.1200/JCO.2003.04.040
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
10.1093/ANNONC/MDH393
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
S. Chan (2004)
10.1016/j.breast.2010.05.008
Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
D. Bernardi (2010)
10.1023/A:1011655503511
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
L. Gianni (2001)
10.1016/j.breast.2010.01.018
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
M. Venturini (2010)
10.1200/JCO.1997.15.9.3149
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
M. Piccart (1997)
10.1200/JCO.1998.16.10.3439
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
R. Fossati (1998)
Anthracyclines in the treatment of cancer. An overview.
G. Hortobagyi (1997)
10.1093/annonc/mdq392
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).
M. S. Rosati (2011)
10.1002/14651858.CD003372.pub3
Single agent versus combination chemotherapy for metastatic breast cancer.
S. Carrick (2009)
10.3322/caac.20107
Global cancer statistics
A. Jemal (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar